Key result
TAVI effectively treats high-risk severe symptomatic AS while new devices simplify the procedure.
This review highlights the advances, current evidence, and strategies to address limitations of TAVI in patients with severe symptomatic aortic stenosis and high operative risk.
Answers are grounded in this paper and cite their sources.
May support TAVI in high-risk severe AS; leaves open durability, selection, and long-term outcome questions.
Cumulative evidence has demonstrated that transcatheter aortic valve implantation (TAVI) constitutes an effective treatment option for patients with severe symptomatic aortic stenosis and a high operative risk. New valve designs and TAVI-enabling devices have simplified the procedure, reduced the risk of complications, and broadened the applications of this treatment. The global adoption of TAVI allows us to appreciate the advantages, potentialities and caveats of the technology, identify patients who would benefit from TAVI and stratify more accurately the risk of complications. The focus of this article is to discuss the advances in this field, present the current evidence, and highlight the developments and strategies proposed to address the limitations of TAVI treatment.
No takes yet. Share an insight, caveat, or question.
Bourantas et al. (2013) conducted a review in Severe symptomatic aortic stenosis with high operative risk. Transcatheter aortic valve implantation (TAVI) was evaluated. Transcatheter aortic valve implantation is an effective treatment option for patients with severe symptomatic aortic stenosis and high operative risk, with new devices simplifying the procedure.
Synapse has enriched 10 related papers. Consider them for comparative context: